WCM Investment Management LLC Has $5.71 Million Stake in IDEAYA Biosciences, Inc. $IDYA

WCM Investment Management LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 17.2% during the 1st quarter, HoldingsChannel reports. The fund owned 181,593 shares of the company’s stock after selling 37,675 shares during the quarter. WCM Investment Management LLC’s holdings in IDEAYA Biosciences were worth $5,711,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after buying an additional 380 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after buying an additional 436 shares in the last quarter. Russell Investments Group Ltd. grew its position in IDEAYA Biosciences by 5.2% in the fourth quarter. Russell Investments Group Ltd. now owns 9,683 shares of the company’s stock valued at $335,000 after acquiring an additional 476 shares during the period. Farther Finance Advisors LLC grew its position in IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares during the period. Finally, Comerica Bank lifted its holdings in shares of IDEAYA Biosciences by 36.5% during the fourth quarter. Comerica Bank now owns 2,514 shares of the company’s stock valued at $87,000 after acquiring an additional 672 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Upgrades and Downgrades

IDYA has been the topic of several analyst reports. Wall Street Zen raised shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Guggenheim lifted their price target on shares of IDEAYA Biosciences from $50.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Truist Financial reduced their price target on shares of IDEAYA Biosciences from $65.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Citigroup reaffirmed a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Finally, Royal Bank Of Canada cut their target price on shares of IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating for the company in a research note on Tuesday, July 7th. Fifteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.25.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ:IDYA opened at $35.45 on Tuesday. The business has a fifty day moving average of $32.41 and a 200-day moving average of $32.65. IDEAYA Biosciences, Inc. has a twelve month low of $21.33 and a twelve month high of $40.58. The firm has a market cap of $3.11 billion, a PE ratio of -22.16 and a beta of -0.09.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. During the same quarter last year, the business posted ($0.82) EPS. The firm’s quarterly revenue was down 39.4% compared to the same quarter last year. On average, analysts anticipate that IDEAYA Biosciences, Inc. will post -4.1 EPS for the current fiscal year.

Insider Activity

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total transaction of $382,095.50. Following the sale, the chief accounting officer directly owned 26,466 shares of the company’s stock, valued at $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.